A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

People with obesity who take weight loss and diabetes drugs like Ozempic and Mounjaro could face a lower risk of cancer compared to those with obesity who do not. Looking at 14 cancers, of which 13 ...

A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and ...

As cancer progression has been linked with high glucose, adiposity, insulin resistance, and systemic inflammation, investigators studied several glucose-lowering drugs in relationship to cancer ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...

Serena Williams revealed how she turned her health around with the help of a GLP-1 medication after she struggled to lose ...